Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-03084014 + docetaxel
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PF-03084014 + docetaxel is a combination therapy consisting of PF-03084014 (also known as nirogacestat), a selective, small-molecule γ-secretase inhibitor, and docetaxel, a well-established taxane chemotherapeutic agent. PF-03084014 inhibits the γ-secretase complex, thereby blocking NOTCH receptor activation and downstream signaling pathways implicated in tumor growth and survival. Docetaxel disrupts microtubule function during cell division, leading to apoptosis in rapidly dividing cancer cells. This combination is under investigation for synergistic antitumor effects in advanced solid tumors.
- Other names
- nirogacestat + docetaxel
02
Targets
GSEC (Gamma-Secretase Complex)NOTCH (Neurogenic locus notch homolog protein 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PF-03084014 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-03084014 + docetaxel.